1. Home
  2. BMEA vs INVE Comparison

BMEA vs INVE Comparison

Compare BMEA & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

N/A

Current Price

$1.43

Market Cap

90.5M

Sector

Health Care

ML Signal

N/A

Logo Identiv Inc.

INVE

Identiv Inc.

N/A

Current Price

$3.38

Market Cap

74.8M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
BMEA
INVE
Founded
2017
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer peripheral equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
90.5M
74.8M
IPO Year
2021
1997

Fundamental Metrics

Financial Performance
Metric
BMEA
INVE
Price
$1.43
$3.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
2
Target Price
$8.71
$5.50
AVG Volume (30 Days)
767.7K
34.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
1182.76
EPS
N/A
N/A
Revenue
N/A
$60,219,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$11.82
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.21
52 Week Low
$0.87
$2.86
52 Week High
$3.08
$4.07

Technical Indicators

Market Signals
Indicator
BMEA
INVE
Relative Strength Index (RSI) 56.24 55.51
Support Level $1.24 $3.15
Resistance Level $1.43 $3.49
Average True Range (ATR) 0.09 0.17
MACD 0.01 0.03
Stochastic Oscillator 66.67 44.85

Price Performance

Historical Comparison
BMEA
INVE

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

About INVE Identiv Inc.

Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.

Share on Social Networks: